View Financial HealthUFP Technologies 配当と自社株買い配当金 基準チェック /06UFP Technologies配当金を支払った記録がありません。主要情報n/a配当利回り0.2%バイバック利回り総株主利回り0.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 05UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law.お知らせ • May 27UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human ResourcesUFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition.Recent Insider Transactions • May 17Lead Independent Director recently sold US$635k worth of stockOn the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly US$222 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.7m more than they bought in the last 12 months.ライブニュース • May 16UFP Technologies Grows Medical Revenue and Expands Facilities as New CEO Prepares to Take OverQ1 2026 revenue grew 4.1%, with medical sales up 5.9% and non-medical sales down 15%, reflecting continued focus on healthcare customers. Non-GAAP EPS came in at $2.48, 7.4% above analyst expectations, with an adjusted operating margin of 16.9% in line with the prior year. The company is adding manufacturing capacity in the Dominican Republic and planning further expansion in Asia-Pacific, while four new medical programs are expected to lift revenue in the second half of 2026. A CEO transition to Mitch Rock is set for June, and management reported that a February 2026 cyber incident and reduced tariff impacts have not had a material effect on operations or financials. The combination of steady margins, capacity build-out and new medical programs indicates that management is prioritizing higher-value MedTech opportunities over more cyclical non-medical markets. Investors may want to watch execution on the new facilities and leadership transition, as well as the ramp of those medical programs, since delays or higher start-up costs could weigh on profitability in the near term.Recent Insider Transactions Derivative • May 14Lead Independent Director notifies of intention to sell stockDaniel Croteau intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of May. If the sale is conducted around the recent share price of US$222, it would amount to US$635k. Since June 2025, Daniel's direct individual holding has decreased from 1.79k shares to 230.00. Company insiders have collectively sold US$999k more than they bought, via options and on-market transactions in the last 12 months.分析記事 • May 13UFP Technologies, Inc. (NASDAQ:UFPT) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkInvestors in UFP Technologies, Inc. ( NASDAQ:UFPT ) had a good week, as its shares rose 3.8% to close at US$221...Reported Earnings • May 06First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: US$2.27 (up from US$2.24 in 1Q 2025). Revenue: US$154.2m (up 4.1% from 1Q 2025). Net income: US$17.5m (up 1.8% from 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 14% per year.お知らせ • May 04UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026.お知らせ • May 01UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026Reported Earnings • Feb 25Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$8.87 (up from US$7.69 in FY 2024). Revenue: US$602.8m (up 20% from FY 2024). Net income: US$68.3m (up 16% from FY 2024). Profit margin: 11% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 20UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026分析記事 • Feb 07UFP Technologies' (NASDAQ:UFPT) Returns On Capital Are Heading HigherFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Jan 14Is Now The Time To Look At Buying UFP Technologies, Inc. (NASDAQ:UFPT)?UFP Technologies, Inc. ( NASDAQ:UFPT ), might not be a large cap stock, but it received a lot of attention from a...Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to US$255, the stock trades at a forward P/E ratio of 27x. Average trailing P/E is 31x in the Medical Equipment industry in the US. Total returns to shareholders of 119% over the past three years.分析記事 • Jan 01UFP Technologies (NASDAQ:UFPT) Could Easily Take On More DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...お知らせ • Dec 03+ 1 more updateUFP Technologies, Inc. Technologies Announces Board ChangesUFP Technologies, Inc. announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. Mr. Bailly intends to remain on the Board of Directors of the Company (the Board"). Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company's Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company's Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company's Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.Recent Insider Transactions • Nov 14General Counsel recently sold US$416k worth of stockOn the 6th of November, Christopher Litterio sold around 2k shares on-market at roughly US$227 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$592k. Insiders have been net sellers, collectively disposing of US$2.8m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Nov 06General Counsel notifies of intention to sell stockChristopher Litterio intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of November. If the sale is conducted around the recent share price of US$233, it would amount to US$426k. Since March 2025, Christopher's direct individual holding has decreased from 10.38k shares to 9.32k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Nov 04Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: US$2.12. Revenue: US$154.6m (up 6.5% from 3Q 2024). Net income: US$16.4m (flat on 3Q 2024). Profit margin: 11% (in line with 3Q 2024). Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.お知らせ • Oct 29UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025分析記事 • Sep 23Should You Be Adding UFP Technologies (NASDAQ:UFPT) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Recent Insider Transactions • Sep 10Lead Independent Director recently sold US$592k worth of stockOn the 5th of September, Daniel Croteau sold around 3k shares on-market at roughly US$206 per share. This transaction amounted to 93% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$17m more than they bought in the last 12 months.Buy Or Sell Opportunity • Aug 06Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.7% to US$214. The fair value is estimated to be US$289, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 27% in the next 2 years.ナラティブの更新 • Aug 06Dominican Expansion And Refined Operations Will Spark Future ProgressDespite a notable decline in consensus revenue growth forecasts, the analyst price target for UFP Technologies has increased to $329.50, reflecting improved sentiment or factors offsetting lower growth expectations. What's in the News UFP Technologies was added to the Russell 2000 Dynamic Index.Reported Earnings • Aug 05Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: EPS: US$2.23 (up from US$1.77 in 2Q 2024). Revenue: US$151.2m (up 37% from 2Q 2024). Net income: US$17.2m (up 27% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 30UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025分析記事 • Jul 28Investors Met With Slowing Returns on Capital At UFP Technologies (NASDAQ:UFPT)If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...お知らせ • Jul 17UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility. For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025.分析記事 • Jul 16Are Investors Undervaluing UFP Technologies, Inc. (NASDAQ:UFPT) By 25%?Key Insights Using the 2 Stage Free Cash Flow to Equity, UFP Technologies fair value estimate is US$307 Current share...Buy Or Sell Opportunity • Jul 07Now 21% undervaluedOver the last 90 days, the stock has risen 25% to US$241. The fair value is estimated to be US$306, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.分析記事 • Jul 02UFP Technologies (NASDAQ:UFPT) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Jun 13Now 20% undervaluedOver the last 90 days, the stock has risen 11% to US$233. The fair value is estimated to be US$292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.Buy Or Sell Opportunity • May 21Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to US$229. The fair value is estimated to be US$288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.Recent Insider Transactions • May 14General Counsel recently sold US$324k worth of stockOn the 8th of May, Christopher Litterio sold around 1k shares on-market at roughly US$220 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.6m. Insiders have been net sellers, collectively disposing of US$50m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$244, the stock trades at a forward P/E ratio of 28x. Average trailing P/E is 31x in the Medical Equipment industry in the US. Total returns to shareholders of 221% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$292 per share.新しいナラティブ • May 11Safe Patient Handling Expansion And Dominican Production Will Advance MedTech Expansion in the safe patient handling space and Dominican operations is expected to boost revenue and margins through efficiency and shared savings. 分析記事 • May 09Results: UFP Technologies, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesUFP Technologies, Inc. ( NASDAQ:UFPT ) just released its latest first-quarter results and things are looking bullish...Price Target Changed • May 07Price target decreased by 18% to US$311Down from US$379, the current price target is an average from 2 analysts. New target price is 42% above last closing price of US$220. Stock is down 13% over the past year. The company is forecast to post earnings per share of US$8.50 for next year compared to US$7.69 last year.Reported Earnings • May 06First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$2.24 (up from US$1.66 in 1Q 2024). Revenue: US$148.1m (up 41% from 1Q 2024). Net income: US$17.2m (up 35% from 1Q 2024). Profit margin: 12% (in line with 1Q 2024). Revenue exceeded analyst estimates by 5.9%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 05At US$202, Is It Time To Put UFP Technologies, Inc. (NASDAQ:UFPT) On Your Watch List?UFP Technologies, Inc. ( NASDAQ:UFPT ), is not the largest company out there, but it saw significant share price...お知らせ • May 01UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025.お知らせ • Apr 30UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025分析記事 • Mar 27Is UFP Technologies, Inc. (NASDAQ:UFPT) Trading At A 49% Discount?Key Insights The projected fair value for UFP Technologies is US$398 based on 2 Stage Free Cash Flow to Equity UFP...分析記事 • Mar 14We Ran A Stock Scan For Earnings Growth And UFP Technologies (NASDAQ:UFPT) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Recent Insider Transactions Derivative • Mar 09Independent Director notifies of intention to sell stockCynthia Feldmann intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of February. If the sale is conducted around the recent share price of US$231, it would amount to US$636k. Since June 2024, Cynthia's direct individual holding has decreased from 4.47k shares to 3.82k. Company insiders have collectively sold US$50m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Mar 05Lead Independent Director recently sold US$1.6m worth of stockOn the 27th of February, Daniel Croteau sold around 7k shares on-market at roughly US$228 per share. This transaction amounted to 81% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$50m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Feb 28Lead Independent Director notifies of intention to sell stockDaniel Croteau intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of February. If the sale is conducted around the recent share price of US$228, it would amount to US$1.6m. Since June 2024, Daniel has owned 8.40k shares directly. Company insiders have collectively sold US$49m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Feb 25Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: US$7.69 (up from US$5.89 in FY 2023). Revenue: US$504.4m (up 26% from FY 2023). Net income: US$59.0m (up 31% from FY 2023). Profit margin: 12% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 19UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025分析記事 • Feb 13UFP Technologies (NASDAQ:UFPT) Hasn't Managed To Accelerate Its ReturnsFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Jan 17UFP Technologies (NASDAQ:UFPT) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 31What You Can Learn From UFP Technologies, Inc.'s (NASDAQ:UFPT) P/E After Its 26% Share Price CrashUFP Technologies, Inc. ( NASDAQ:UFPT ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Dec 27Should You Think About Buying UFP Technologies, Inc. (NASDAQ:UFPT) Now?While UFP Technologies, Inc. ( NASDAQ:UFPT ) might not have the largest market cap around , it saw significant share...Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to US$242, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 264% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$178 per share.分析記事 • Nov 29Should You Be Adding UFP Technologies (NASDAQ:UFPT) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Nov 20Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$290, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 303% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$180 per share.Recent Insider Transactions • Nov 14CEO & Chairman recently sold US$8.8m worth of stockOn the 11th of November, R. Bailly sold around 25k shares on-market at roughly US$348 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$14m. R. has been a net seller over the last 12 months, reducing personal holdings by US$53m.Recent Insider Transactions Derivative • Nov 13Independent Director notifies of intention to sell stockSymeria Hudson intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$341, it would amount to US$782k. Since June 2024, Symeria has owned 945.00 shares directly. Company insiders have collectively sold US$52m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Nov 08Results: UFP Technologies, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsUFP Technologies, Inc. ( NASDAQ:UFPT ) investors will be delighted, with the company turning in some strong numbers...Reported Earnings • Nov 05Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Oct 29Returns On Capital Are Showing Encouraging Signs At UFP Technologies (NASDAQ:UFPT)If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...分析記事 • Oct 16Here's Why UFP Technologies (NASDAQ:UFPT) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Oct 03Is UFP Technologies, Inc. (NASDAQ:UFPT) Trading At A 43% Discount?Key Insights The projected fair value for UFP Technologies is US$538 based on 2 Stage Free Cash Flow to Equity Current...Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$355, the stock trades at a forward P/E ratio of 46x. Average trailing P/E is 40x in the Medical Equipment industry in the US. Total returns to shareholders of 465% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$538 per share.分析記事 • Sep 19What Is UFP Technologies, Inc.'s (NASDAQ:UFPT) Share Price Doing?UFP Technologies, Inc. ( NASDAQ:UFPT ), is not the largest company out there, but it received a lot of attention from a...お知らせ • Aug 27UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024.Recent Insider Transactions • Aug 08CFO, Senior VP & Treasurer recently sold US$4.0m worth of stockOn the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly US$304 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by US$4.0m.分析記事 • Aug 03UFP Technologies, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearA week ago, UFP Technologies, Inc. ( NASDAQ:UFPT ) came out with a strong set of quarterly numbers that could...Reported Earnings • Aug 01Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jul 17There's Reason For Concern Over UFP Technologies, Inc.'s (NASDAQ:UFPT) Massive 27% Price JumpUFP Technologies, Inc. ( NASDAQ:UFPT ) shares have continued their recent momentum with a 27% gain in the last month...お知らせ • Jul 17+ 1 more updateUFP Technologies, Inc. (NasdaqCM:UFPT) acquired Marble Medical Inc. for $5 million from Joseph J. Audie.UFP Technologies, Inc. (NasdaqCM:UFPT) signed a Stock Purchase Agreement to acquire Marble Medical Inc. for $5 million from Joseph J. Audie on June 24, 2024. The Marble shares were acquired for an aggregate purchase price of $4.5 million in cash plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024 and 2025. In a related transaction UFP Technologies, Inc. acquired Welch Fluorocarbon. The aggregate purchase price at closing was approximately 4.5 times the Marble adjusted EBITDA. Marble Medical Inc. has annual sales of approximately $5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Marble Medical Inc. for $5 million from Joseph J. Audie on July 16, 2024.分析記事 • Jul 12The Return Trends At UFP Technologies (NASDAQ:UFPT) Look PromisingThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...Price Target Changed • Jul 02Price target increased by 19% to US$312Up from US$263, the current price target is an average from 2 analysts. New target price is 10.0% above last closing price of US$284. Stock is up 44% over the past year. The company is forecast to post earnings per share of US$6.74 for next year compared to US$5.89 last year.Seeking Alpha • Jul 02UFP Technologies: Impressive Has Become ExpensiveSummary UFP Technologies, Inc. has long been somewhat of a hidden gem, active in the manufacturing of custom medical components. The company acquires AJR Enterprises at a substantial discount, boosting sales and earnings growth potential. Valuation multiples have steadily increased over time, with shares trading at a premium in terms of earnings multiples. With UFP Technologies trading at fresh highs, I fail to see the appeal as expectations have risen considerably, but the company definitely deserves a spot on my watch list. Read the full article on Seeking Alpha分析記事 • Jun 22Is UFP Technologies (NASDAQ:UFPT) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • May 30Unpleasant Surprises Could Be In Store For UFP Technologies, Inc.'s (NASDAQ:UFPT) SharesUFP Technologies, Inc.'s ( NASDAQ:UFPT ) price-to-earnings (or "P/E") ratio of 42.1x might make it look like a strong...Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to US$253, the stock trades at a forward P/E ratio of 37x. Average trailing P/E is 38x in the Medical Equipment industry in the US. Total returns to shareholders of 352% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$105 per share.Major Estimate Revision • May 08Consensus EPS estimates increase by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$431.7m to US$438.0m. EPS estimate increased from US$5.93 to US$6.62 per share. Net income forecast to grow 11% next year vs 18% growth forecast for Medical Equipment industry in the US. Consensus price target up from US$243 to US$263. Share price rose 23% to US$253 over the past week.Reported Earnings • May 01First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Apr 29UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof.分析記事 • Apr 11Should You Be Adding UFP Technologies (NASDAQ:UFPT) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Mar 27At US$241, Is UFP Technologies, Inc. (NASDAQ:UFPT) Worth Looking At Closely?UFP Technologies, Inc. ( NASDAQ:UFPT ), is not the largest company out there, but it led the NASDAQCM gainers with a...Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$226, the stock trades at a forward P/E ratio of 38x. Average trailing P/E is 40x in the Medical Equipment industry in the US. Total returns to shareholders of 355% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$329 per share.分析記事 • Mar 15UFP Technologies (NASDAQ:UFPT) Is Looking To Continue Growing Its Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Recent Insider Transactions Derivative • Mar 13VP & COO of MedTech notifies of intention to sell stockSteven Cardin intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of March. If the sale is conducted around the recent share price of US$198, it would amount to US$484k. Since June 2023, Steven has owned 2.44k shares directly. Company insiders have collectively sold US$27m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Mar 03CEO & Chairman recently sold US$5.7m worth of stockOn the 23rd of February, R. Bailly sold around 27k shares on-market at roughly US$209 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by US$20m.Recent Insider Transactions Derivative • Feb 25Independent Director notifies of intention to sell stockCynthia Feldmann intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of February. If the sale is conducted around the recent share price of US$214, it would amount to US$369k. Since June 2023, Cynthia has owned 4.17k shares directly. Company insiders have collectively sold US$20m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Feb 24US$231 - That's What Analysts Think UFP Technologies, Inc. (NASDAQ:UFPT) Is Worth After These ResultsInvestors in UFP Technologies, Inc. ( NASDAQ:UFPT ) had a good week, as its shares rose 9.0% to close at US$211...Price Target Changed • Feb 22Price target increased by 23% to US$231Up from US$188, the current price target is provided by 1 analyst. New target price is 7.9% above last closing price of US$214. Stock is up 84% over the past year. The company is forecast to post earnings per share of US$5.77 for next year compared to US$5.89 last year.Reported Earnings • Feb 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Feb 22UFP Technologies, Inc.'s (NASDAQ:UFPT) 29% Price Boost Is Out Of Tune With EarningsUFP Technologies, Inc. ( NASDAQ:UFPT ) shares have had a really impressive month, gaining 29% after a shaky period...お知らせ • Feb 06UFP Technologies, Inc. Announces Executive ChangesUFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer.分析記事 • Jan 31An Intrinsic Calculation For UFP Technologies, Inc. (NASDAQ:UFPT) Suggests It's 24% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, UFP Technologies fair value estimate is US$227 UFP...分析記事 • Jan 18UFP Technologies (NASDAQ:UFPT) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 03Some Confidence Is Lacking In UFP Technologies, Inc.'s (NASDAQ:UFPT) P/EUFP Technologies, Inc.'s ( NASDAQ:UFPT ) price-to-earnings (or "P/E") ratio of 30.3x might make it look like a strong...Recent Insider Transactions • Dec 18Chairman of the Board of Directors recently sold US$3.7m worth of stockOn the 14th of December, R. Bailly sold around 20k shares on-market at roughly US$181 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by US$12m.決済の安定と成長配当データの取得安定した配当: UFPTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: UFPTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場UFP Technologies 配当利回り対市場UFPT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (UFPT)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Medical Equipment)2.1%アナリスト予想 (UFPT) (最長3年)n/a注目すべき配当: UFPTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: UFPTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: UFPTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: UFPTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 14:15終値2026/06/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋UFP Technologies, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Jonathan TanwantengCJS Securities, Inc.Justin AgesCJS Securities, Inc.Brett FishbinKeyBanc Capital Markets Inc.4 その他のアナリストを表示
お知らせ • Jun 05UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law.
お知らせ • May 27UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human ResourcesUFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition.
Recent Insider Transactions • May 17Lead Independent Director recently sold US$635k worth of stockOn the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly US$222 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.7m more than they bought in the last 12 months.
ライブニュース • May 16UFP Technologies Grows Medical Revenue and Expands Facilities as New CEO Prepares to Take OverQ1 2026 revenue grew 4.1%, with medical sales up 5.9% and non-medical sales down 15%, reflecting continued focus on healthcare customers. Non-GAAP EPS came in at $2.48, 7.4% above analyst expectations, with an adjusted operating margin of 16.9% in line with the prior year. The company is adding manufacturing capacity in the Dominican Republic and planning further expansion in Asia-Pacific, while four new medical programs are expected to lift revenue in the second half of 2026. A CEO transition to Mitch Rock is set for June, and management reported that a February 2026 cyber incident and reduced tariff impacts have not had a material effect on operations or financials. The combination of steady margins, capacity build-out and new medical programs indicates that management is prioritizing higher-value MedTech opportunities over more cyclical non-medical markets. Investors may want to watch execution on the new facilities and leadership transition, as well as the ramp of those medical programs, since delays or higher start-up costs could weigh on profitability in the near term.
Recent Insider Transactions Derivative • May 14Lead Independent Director notifies of intention to sell stockDaniel Croteau intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of May. If the sale is conducted around the recent share price of US$222, it would amount to US$635k. Since June 2025, Daniel's direct individual holding has decreased from 1.79k shares to 230.00. Company insiders have collectively sold US$999k more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • May 13UFP Technologies, Inc. (NASDAQ:UFPT) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkInvestors in UFP Technologies, Inc. ( NASDAQ:UFPT ) had a good week, as its shares rose 3.8% to close at US$221...
Reported Earnings • May 06First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: US$2.27 (up from US$2.24 in 1Q 2025). Revenue: US$154.2m (up 4.1% from 1Q 2025). Net income: US$17.5m (up 1.8% from 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 14% per year.
お知らせ • May 04UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026.
お知らせ • May 01UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026
Reported Earnings • Feb 25Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$8.87 (up from US$7.69 in FY 2024). Revenue: US$602.8m (up 20% from FY 2024). Net income: US$68.3m (up 16% from FY 2024). Profit margin: 11% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 20UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026
分析記事 • Feb 07UFP Technologies' (NASDAQ:UFPT) Returns On Capital Are Heading HigherFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Jan 14Is Now The Time To Look At Buying UFP Technologies, Inc. (NASDAQ:UFPT)?UFP Technologies, Inc. ( NASDAQ:UFPT ), might not be a large cap stock, but it received a lot of attention from a...
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to US$255, the stock trades at a forward P/E ratio of 27x. Average trailing P/E is 31x in the Medical Equipment industry in the US. Total returns to shareholders of 119% over the past three years.
分析記事 • Jan 01UFP Technologies (NASDAQ:UFPT) Could Easily Take On More DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
お知らせ • Dec 03+ 1 more updateUFP Technologies, Inc. Technologies Announces Board ChangesUFP Technologies, Inc. announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. Mr. Bailly intends to remain on the Board of Directors of the Company (the Board"). Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company's Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company's Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company's Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.
Recent Insider Transactions • Nov 14General Counsel recently sold US$416k worth of stockOn the 6th of November, Christopher Litterio sold around 2k shares on-market at roughly US$227 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$592k. Insiders have been net sellers, collectively disposing of US$2.8m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Nov 06General Counsel notifies of intention to sell stockChristopher Litterio intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of November. If the sale is conducted around the recent share price of US$233, it would amount to US$426k. Since March 2025, Christopher's direct individual holding has decreased from 10.38k shares to 9.32k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Nov 04Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: US$2.12. Revenue: US$154.6m (up 6.5% from 3Q 2024). Net income: US$16.4m (flat on 3Q 2024). Profit margin: 11% (in line with 3Q 2024). Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
お知らせ • Oct 29UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025
分析記事 • Sep 23Should You Be Adding UFP Technologies (NASDAQ:UFPT) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Recent Insider Transactions • Sep 10Lead Independent Director recently sold US$592k worth of stockOn the 5th of September, Daniel Croteau sold around 3k shares on-market at roughly US$206 per share. This transaction amounted to 93% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$17m more than they bought in the last 12 months.
Buy Or Sell Opportunity • Aug 06Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.7% to US$214. The fair value is estimated to be US$289, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 27% in the next 2 years.
ナラティブの更新 • Aug 06Dominican Expansion And Refined Operations Will Spark Future ProgressDespite a notable decline in consensus revenue growth forecasts, the analyst price target for UFP Technologies has increased to $329.50, reflecting improved sentiment or factors offsetting lower growth expectations. What's in the News UFP Technologies was added to the Russell 2000 Dynamic Index.
Reported Earnings • Aug 05Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: EPS: US$2.23 (up from US$1.77 in 2Q 2024). Revenue: US$151.2m (up 37% from 2Q 2024). Net income: US$17.2m (up 27% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 30UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025
分析記事 • Jul 28Investors Met With Slowing Returns on Capital At UFP Technologies (NASDAQ:UFPT)If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
お知らせ • Jul 17UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility. For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025.
分析記事 • Jul 16Are Investors Undervaluing UFP Technologies, Inc. (NASDAQ:UFPT) By 25%?Key Insights Using the 2 Stage Free Cash Flow to Equity, UFP Technologies fair value estimate is US$307 Current share...
Buy Or Sell Opportunity • Jul 07Now 21% undervaluedOver the last 90 days, the stock has risen 25% to US$241. The fair value is estimated to be US$306, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.
分析記事 • Jul 02UFP Technologies (NASDAQ:UFPT) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Jun 13Now 20% undervaluedOver the last 90 days, the stock has risen 11% to US$233. The fair value is estimated to be US$292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.
Buy Or Sell Opportunity • May 21Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to US$229. The fair value is estimated to be US$288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.
Recent Insider Transactions • May 14General Counsel recently sold US$324k worth of stockOn the 8th of May, Christopher Litterio sold around 1k shares on-market at roughly US$220 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.6m. Insiders have been net sellers, collectively disposing of US$50m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$244, the stock trades at a forward P/E ratio of 28x. Average trailing P/E is 31x in the Medical Equipment industry in the US. Total returns to shareholders of 221% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$292 per share.
新しいナラティブ • May 11Safe Patient Handling Expansion And Dominican Production Will Advance MedTech Expansion in the safe patient handling space and Dominican operations is expected to boost revenue and margins through efficiency and shared savings.
分析記事 • May 09Results: UFP Technologies, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesUFP Technologies, Inc. ( NASDAQ:UFPT ) just released its latest first-quarter results and things are looking bullish...
Price Target Changed • May 07Price target decreased by 18% to US$311Down from US$379, the current price target is an average from 2 analysts. New target price is 42% above last closing price of US$220. Stock is down 13% over the past year. The company is forecast to post earnings per share of US$8.50 for next year compared to US$7.69 last year.
Reported Earnings • May 06First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$2.24 (up from US$1.66 in 1Q 2024). Revenue: US$148.1m (up 41% from 1Q 2024). Net income: US$17.2m (up 35% from 1Q 2024). Profit margin: 12% (in line with 1Q 2024). Revenue exceeded analyst estimates by 5.9%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 05At US$202, Is It Time To Put UFP Technologies, Inc. (NASDAQ:UFPT) On Your Watch List?UFP Technologies, Inc. ( NASDAQ:UFPT ), is not the largest company out there, but it saw significant share price...
お知らせ • May 01UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025.
お知らせ • Apr 30UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025
分析記事 • Mar 27Is UFP Technologies, Inc. (NASDAQ:UFPT) Trading At A 49% Discount?Key Insights The projected fair value for UFP Technologies is US$398 based on 2 Stage Free Cash Flow to Equity UFP...
分析記事 • Mar 14We Ran A Stock Scan For Earnings Growth And UFP Technologies (NASDAQ:UFPT) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Recent Insider Transactions Derivative • Mar 09Independent Director notifies of intention to sell stockCynthia Feldmann intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of February. If the sale is conducted around the recent share price of US$231, it would amount to US$636k. Since June 2024, Cynthia's direct individual holding has decreased from 4.47k shares to 3.82k. Company insiders have collectively sold US$50m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Mar 05Lead Independent Director recently sold US$1.6m worth of stockOn the 27th of February, Daniel Croteau sold around 7k shares on-market at roughly US$228 per share. This transaction amounted to 81% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$50m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Feb 28Lead Independent Director notifies of intention to sell stockDaniel Croteau intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of February. If the sale is conducted around the recent share price of US$228, it would amount to US$1.6m. Since June 2024, Daniel has owned 8.40k shares directly. Company insiders have collectively sold US$49m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Feb 25Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: US$7.69 (up from US$5.89 in FY 2023). Revenue: US$504.4m (up 26% from FY 2023). Net income: US$59.0m (up 31% from FY 2023). Profit margin: 12% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 19UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025
分析記事 • Feb 13UFP Technologies (NASDAQ:UFPT) Hasn't Managed To Accelerate Its ReturnsFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Jan 17UFP Technologies (NASDAQ:UFPT) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Dec 31What You Can Learn From UFP Technologies, Inc.'s (NASDAQ:UFPT) P/E After Its 26% Share Price CrashUFP Technologies, Inc. ( NASDAQ:UFPT ) shareholders that were waiting for something to happen have been dealt a blow...
分析記事 • Dec 27Should You Think About Buying UFP Technologies, Inc. (NASDAQ:UFPT) Now?While UFP Technologies, Inc. ( NASDAQ:UFPT ) might not have the largest market cap around , it saw significant share...
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to US$242, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 264% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$178 per share.
分析記事 • Nov 29Should You Be Adding UFP Technologies (NASDAQ:UFPT) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$290, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 303% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$180 per share.
Recent Insider Transactions • Nov 14CEO & Chairman recently sold US$8.8m worth of stockOn the 11th of November, R. Bailly sold around 25k shares on-market at roughly US$348 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$14m. R. has been a net seller over the last 12 months, reducing personal holdings by US$53m.
Recent Insider Transactions Derivative • Nov 13Independent Director notifies of intention to sell stockSymeria Hudson intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$341, it would amount to US$782k. Since June 2024, Symeria has owned 945.00 shares directly. Company insiders have collectively sold US$52m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Nov 08Results: UFP Technologies, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsUFP Technologies, Inc. ( NASDAQ:UFPT ) investors will be delighted, with the company turning in some strong numbers...
Reported Earnings • Nov 05Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Oct 29Returns On Capital Are Showing Encouraging Signs At UFP Technologies (NASDAQ:UFPT)If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
分析記事 • Oct 16Here's Why UFP Technologies (NASDAQ:UFPT) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Oct 03Is UFP Technologies, Inc. (NASDAQ:UFPT) Trading At A 43% Discount?Key Insights The projected fair value for UFP Technologies is US$538 based on 2 Stage Free Cash Flow to Equity Current...
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$355, the stock trades at a forward P/E ratio of 46x. Average trailing P/E is 40x in the Medical Equipment industry in the US. Total returns to shareholders of 465% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$538 per share.
分析記事 • Sep 19What Is UFP Technologies, Inc.'s (NASDAQ:UFPT) Share Price Doing?UFP Technologies, Inc. ( NASDAQ:UFPT ), is not the largest company out there, but it received a lot of attention from a...
お知らせ • Aug 27UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024.
Recent Insider Transactions • Aug 08CFO, Senior VP & Treasurer recently sold US$4.0m worth of stockOn the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly US$304 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by US$4.0m.
分析記事 • Aug 03UFP Technologies, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearA week ago, UFP Technologies, Inc. ( NASDAQ:UFPT ) came out with a strong set of quarterly numbers that could...
Reported Earnings • Aug 01Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jul 17There's Reason For Concern Over UFP Technologies, Inc.'s (NASDAQ:UFPT) Massive 27% Price JumpUFP Technologies, Inc. ( NASDAQ:UFPT ) shares have continued their recent momentum with a 27% gain in the last month...
お知らせ • Jul 17+ 1 more updateUFP Technologies, Inc. (NasdaqCM:UFPT) acquired Marble Medical Inc. for $5 million from Joseph J. Audie.UFP Technologies, Inc. (NasdaqCM:UFPT) signed a Stock Purchase Agreement to acquire Marble Medical Inc. for $5 million from Joseph J. Audie on June 24, 2024. The Marble shares were acquired for an aggregate purchase price of $4.5 million in cash plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024 and 2025. In a related transaction UFP Technologies, Inc. acquired Welch Fluorocarbon. The aggregate purchase price at closing was approximately 4.5 times the Marble adjusted EBITDA. Marble Medical Inc. has annual sales of approximately $5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Marble Medical Inc. for $5 million from Joseph J. Audie on July 16, 2024.
分析記事 • Jul 12The Return Trends At UFP Technologies (NASDAQ:UFPT) Look PromisingThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...
Price Target Changed • Jul 02Price target increased by 19% to US$312Up from US$263, the current price target is an average from 2 analysts. New target price is 10.0% above last closing price of US$284. Stock is up 44% over the past year. The company is forecast to post earnings per share of US$6.74 for next year compared to US$5.89 last year.
Seeking Alpha • Jul 02UFP Technologies: Impressive Has Become ExpensiveSummary UFP Technologies, Inc. has long been somewhat of a hidden gem, active in the manufacturing of custom medical components. The company acquires AJR Enterprises at a substantial discount, boosting sales and earnings growth potential. Valuation multiples have steadily increased over time, with shares trading at a premium in terms of earnings multiples. With UFP Technologies trading at fresh highs, I fail to see the appeal as expectations have risen considerably, but the company definitely deserves a spot on my watch list. Read the full article on Seeking Alpha
分析記事 • Jun 22Is UFP Technologies (NASDAQ:UFPT) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
分析記事 • May 30Unpleasant Surprises Could Be In Store For UFP Technologies, Inc.'s (NASDAQ:UFPT) SharesUFP Technologies, Inc.'s ( NASDAQ:UFPT ) price-to-earnings (or "P/E") ratio of 42.1x might make it look like a strong...
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to US$253, the stock trades at a forward P/E ratio of 37x. Average trailing P/E is 38x in the Medical Equipment industry in the US. Total returns to shareholders of 352% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$105 per share.
Major Estimate Revision • May 08Consensus EPS estimates increase by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$431.7m to US$438.0m. EPS estimate increased from US$5.93 to US$6.62 per share. Net income forecast to grow 11% next year vs 18% growth forecast for Medical Equipment industry in the US. Consensus price target up from US$243 to US$263. Share price rose 23% to US$253 over the past week.
Reported Earnings • May 01First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Apr 29UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof.
分析記事 • Apr 11Should You Be Adding UFP Technologies (NASDAQ:UFPT) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Mar 27At US$241, Is UFP Technologies, Inc. (NASDAQ:UFPT) Worth Looking At Closely?UFP Technologies, Inc. ( NASDAQ:UFPT ), is not the largest company out there, but it led the NASDAQCM gainers with a...
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$226, the stock trades at a forward P/E ratio of 38x. Average trailing P/E is 40x in the Medical Equipment industry in the US. Total returns to shareholders of 355% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$329 per share.
分析記事 • Mar 15UFP Technologies (NASDAQ:UFPT) Is Looking To Continue Growing Its Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
Recent Insider Transactions Derivative • Mar 13VP & COO of MedTech notifies of intention to sell stockSteven Cardin intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of March. If the sale is conducted around the recent share price of US$198, it would amount to US$484k. Since June 2023, Steven has owned 2.44k shares directly. Company insiders have collectively sold US$27m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Mar 03CEO & Chairman recently sold US$5.7m worth of stockOn the 23rd of February, R. Bailly sold around 27k shares on-market at roughly US$209 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by US$20m.
Recent Insider Transactions Derivative • Feb 25Independent Director notifies of intention to sell stockCynthia Feldmann intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of February. If the sale is conducted around the recent share price of US$214, it would amount to US$369k. Since June 2023, Cynthia has owned 4.17k shares directly. Company insiders have collectively sold US$20m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Feb 24US$231 - That's What Analysts Think UFP Technologies, Inc. (NASDAQ:UFPT) Is Worth After These ResultsInvestors in UFP Technologies, Inc. ( NASDAQ:UFPT ) had a good week, as its shares rose 9.0% to close at US$211...
Price Target Changed • Feb 22Price target increased by 23% to US$231Up from US$188, the current price target is provided by 1 analyst. New target price is 7.9% above last closing price of US$214. Stock is up 84% over the past year. The company is forecast to post earnings per share of US$5.77 for next year compared to US$5.89 last year.
Reported Earnings • Feb 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Feb 22UFP Technologies, Inc.'s (NASDAQ:UFPT) 29% Price Boost Is Out Of Tune With EarningsUFP Technologies, Inc. ( NASDAQ:UFPT ) shares have had a really impressive month, gaining 29% after a shaky period...
お知らせ • Feb 06UFP Technologies, Inc. Announces Executive ChangesUFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer.
分析記事 • Jan 31An Intrinsic Calculation For UFP Technologies, Inc. (NASDAQ:UFPT) Suggests It's 24% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, UFP Technologies fair value estimate is US$227 UFP...
分析記事 • Jan 18UFP Technologies (NASDAQ:UFPT) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jan 03Some Confidence Is Lacking In UFP Technologies, Inc.'s (NASDAQ:UFPT) P/EUFP Technologies, Inc.'s ( NASDAQ:UFPT ) price-to-earnings (or "P/E") ratio of 30.3x might make it look like a strong...
Recent Insider Transactions • Dec 18Chairman of the Board of Directors recently sold US$3.7m worth of stockOn the 14th of December, R. Bailly sold around 20k shares on-market at roughly US$181 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by US$12m.
